Who is sponsoring NCT03764475?

NCT03764475 is sponsored by Arcutis Biotherapeutics, Inc..

What condition does NCT03764475 study?

NCT03764475 studies Plaque Psoriasis.

What is the status of NCT03764475?

NCT03764475 is currently COMPLETED.

Last reviewed 2022-09-02 · How we verify

Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis

NCT03764475 PHASE2 COMPLETED Results posted

This is an open-label, long-term safety study of roflumilast (ARQ-151) 0.3% cream in subjects with chronic plaque psoriasis involving up to 25% total Body Surface Area (BSA). Study medication will be applied by the qualifying subjects topically once daily for 52 weeks at home. Periodic clinic visits will include assessments for clinical safety, application site reactions, and disease improvement or progression.

Details

Lead sponsor	Arcutis Biotherapeutics, Inc.
Phase	PHASE2
Status	COMPLETED
Enrolment	332
Start date	Tue Dec 18 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Oct 08 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Plaque Psoriasis

Interventions

Roflumilast

Countries

Canada, United States